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ORIGINAL RESEARCH

Genomic Context Differs Between Human
Dilated Cardiomyopathy and Hypertrophic
Cardiomyopathy
Megan J. Puckelwartz , PhD*; Lorenzo L. Pesce, PhD*; Lisa M. Dellefave-Castillo , MS;
Matthew T. Wheeler , MD, PhD; Tess D. Pottinger, PhD; Avery C. Robinson, BS; Samuel D. Kearns, BS;
Anthony M. Gacita, PhD; Zachary J. Schoppen , MD; Wenyu Pan, MD; Gene Kim, MD; Jane E. Wilcox, MD, MSc;
Allen S. Anderson , MD; Euan A. Ashley , MD, PhD; Sharlene M. Day , MD; Thomas Cappola, MD, ScM;
Gerald W. Dorn, II, MD; Elizabeth M. McNally , MD, PhD
BACKGROUND: Inherited cardiomyopathies display variable penetrance and expression, and a component of phenotypic variation is genetically determined. To evaluate the genetic contribution to this variable expression, we compared protein coding
variation in the genomes of those with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
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METHODS AND RESULTS: Nonsynonymous single-nucleotide variants (nsSNVs) were ascertained using whole genome sequencing from familial cases of HCM (n=56) or DCM (n=70) and correlated with echocardiographic information. Focusing on nsSNVs in 102 genes linked to inherited cardiomyopathies, we correlated the number of nsSNVs per person with left ventricular
measurements. Principal component analysis and generalized linear models were applied to identify the probability of cardiomyopathy type as it related to the number of nsSNVs in cardiomyopathy genes. The probability of having DCM significantly
increased as the number of cardiomyopathy gene nsSNVs per person increased. The increase in nsSNVs in cardiomyopathy
genes significantly associated with reduced left ventricular ejection fraction and increased left ventricular diameter for individuals carrying a DCM diagnosis, but not for those with HCM. Resampling was used to identify genes with aberrant cumulative
allele frequencies, identifying potential modifier genes for cardiomyopathy.
CONCLUSIONS: Participants with DCM had more nsSNVs per person in cardiomyopathy genes than participants with HCM. The
nsSNV burden in cardiomyopathy genes did not correlate with the probability or manifestation of left ventricular measures in
HCM. These findings support the concept that increased variation in cardiomyopathy genes creates a genetic background
that predisposes to DCM and increased disease severity.
Key Words: dilated cardiomyopathy ■ hypertrophic cardiomyopathy ■ modifier genes ■ variable expressivity ■ variant burden

H

eart failure affects >5 million Americans and is
of growing health and economic concern.1 A
leading cause of heart failure is cardiomyopathy, a disease with a strong heritable component.
The 2 most common forms of cardiomyopathy are
hypertrophic cardiomyopathy (HCM) and dilated
cardiomyopathy (DCM). HCM occurs in 1:200 -500

adults and is characterized by gross hypertrophy of
the septum and left ventricular (LV) free wall.2,3 DCM
is found in ≈1:250 -500 adults and presents with reduced LV ejection fraction (LVEF) and dilation.4,5 Over
100 genes are implicated in the pathogenesis of cardiomyopathy, and most cardiomyopathy is inherited
in an autosomal dominant manner. Two genes, MYH7
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CLINICAL PERSPECTIVE
What Is New?

• Dilated and hypertrophic cardiomyopathy are
highly variable in onset and progression of disease severity, indicating that modifiers, including genetic modifiers, play a role in disease
expression.
• We evaluated and compared genome-
wide
coding variation in dilated cardiomyopathy and
hypertrophic cardiomyopathy cases to query
whether genomic backgrounds differ.

What Are the Clinical Implications?

• We evaluated missense single-nucleotide variation in genes associated with cardiomyopathy
and found that the number of genetic changes
per person increased the probability to having
dilated cardiomyopathy but not hypertrophic
cardiomyopathy and correlated with more severe disease.
• The distinct genetic landscapes between hypertrophic cardiomyopathy and dilated cardiomyopathy suggest that greater genetic variation
in cardiomyopathy genes provokes unfavorable
disease expression in dilated cardiomyopathy.
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Nonstandard Abbreviations and Acronyms
DCM
gnomAD
HCM
IVSd
LVIDd
LVPWd
nsSNV
PC
PCA
WGS

dilated cardiomyopathy
Genome Aggregation Database
hypertrophic cardiomyopathy
interventricular septal end diastole
left ventricle internal diameter end
diastole
left ventricular posterior wall end
diastole
nonsynonymous single-nucleotide
variant
principal component
principal component analysis
whole genome sequencing

and MYBPC3, are responsible for >80% of genetic
HCM, making HCM largely a disease of sarcomere
dysfunction.2,6–8 DCM is more genetically heterogeneous, with mutations in one gene, TTN, accounting
for ≈15% to 20% of inherited DCM; the other mutations are found in genes encoding cytoskeletal,
nucleoskeletal, mitochondrial, myofilament, and calcium handling proteins.5,9,10 A feature of both HCM
and DCM is variable expressivity and penetrance.11

Genetic heterogeneity and variable expressivity imply
a more complex inheritance, and some studies support oligogenic contributions to pathogenesis.12–14
Genetic testing for cardiomyopathies has emerged
as a useful clinical tool for both disease diagnosis and
risk stratification.15,16 Rare variants account for most
primary mutations in inherited cardiomyopathy, with
few hot spots or recurrent mutations. Variant interpretation considers population frequency, in silico tools
of pathogenicity, and previous reports of clinical and
functional outcomes. Current cardiac genetic testing
samples 20 to 100 genes, and depending on the primary indication, gene panel testing has ≈50% sensitivity. This reduced sensitivity or “missing heritability”
for cardiomyopathy may be attributable to multiple
factors, including (1) undiscovered primary or “driver”
gene mutations and/or (2) an oligogenic or modifier genetic mechanism involving the interplay between highly
penetrant variants and the genomic context in which
they are expressed.
Whole genome sequencing (WGS) is an effective
means to determine both rare and common variation.
Herein, we applied WGS to 126 subjects with either
familial HCM or DCM from whom echocardiographic
measurements were available. We examined variation in 102 cardiomyopathy genes routinely assayed
in clinical gene testing panels. Both linear and logistic
regression models revealed that subjects with more
nonsynonymous coding variants per person in the 102
cardiomyopathy genes were significantly more likely
to express a DCM clinical phenotype as opposed to
an HCM phenotype. These data also held true for
high-frequency gene variants in the cardiomyopathy
cohort. The number of cardiomyopathy gene variants
per person also associated with reduced ejection
fraction and increased LV diameter in subjects with
DCM, but not subjects with HCM. These results suggest that distinct genetic landscapes exist between
HCM and DCM and that greater genetic variation in
cardiomyopathy genes may be partially responsible
for the unfavorable ventricular remodeling with reduced systolic function in DCM compared with HCM.

METHODS
Detailed methods available in Data S1. The study
was approved by the Institutional Review Boards at
University of Chicago, Stanford University, University
of Michigan, and Northwestern University. All subjects
provided written informed consent.
Because of the sensitive nature of the data collected
for this study, requests to access the data set from
qualified researchers trained in human subject confidentiality protocols may be sent to Megan Puckelwartz
at Northwestern University.
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Study Subjects
Subjects with nonischemic DCM or HCM with familial
disease were selected for WGS.

Generation of WGS Data
Genomic DNA was determined using the Illumina
HiSeq2000, 2500, or XTen and mapped to National
Center for Biotechnology Information hg19 with
MegaSeq.17 Only genomes with coverage >30×
were included. Variant effects were predicted using
snpEff.18

Ancestry Principal Component Analysis
Principal component analysis (PCA) was used to estimate global ancestry through dimensional reduction.
PCAs were conducted using singular-value decomposition of shared variants using ≈5 million biallelic variants selected from across the genome using PLINK
v1.9 and R 3.2.3.

Echocardiography PCA

Downloaded from http://ahajournals.org by on May 4, 2021

PCA was performed using the R function prcomp (R
statistical software version 3.4.1) on scaled and centered LVEF, LV internal diameter end diastole (LVIDd),
interventricular septal end diastole (IVSd), and LV posterior wall end diastole (LVPWd). All dimensions were
adjusted to body surface area (BSA).

Linear Models
Multivariate and univariate linear models were fit
using the lm function of R (R statistical software version 3.4.1). Model significance was assessed using a
χ2 test on reduction in the residual sum of squares.
The response variables were echocardiographic
measures or their principal components, and the
independent variables were nonsynonymous single-
nucleotide variants (nsSNVs), genetic ancestry, and
platform.

Generalized Linear Model
Multivariate and univariate logistic regressions were
fit using the generalized linear model R function, glm,
with binomial link function. The response variable was
whether a patient had DCM as opposed to HCM.
The number of nsSNVs per patient was used as an
independent variable in the primary analysis. Variant
frequency subsets, defined by Genome Aggregation
Database (gnomAD) exome allele frequency in both the
cardiomyopathy genes and across all high-expression
heart genes, were used for secondary analysis. P values correspond to the R analysis of deviance test function and therefore refer to comparison between nested
models.

Genetic Landscape of DCM and HCM

Resampling-Based Estimation of Excess
Nonsynonymous Variation
A bootstrap approach was designed where each random sample with replacement was taken from the
126-subject set without constraining for cardiomyopathy subtype, sex, or ancestry to mimic the original
sample collection method. We calculated excess allele
counts, subtracting baseline values computed assuming ancestral gnomAD exome frequencies for African
ancestry and non-Finnish European ancestry as reference values, including the sex chromosome number
in each subject in the sample. Once corrected, allele
numbers were summed over each of the cardiomyopathy genes, then in high-expression heart genes, creating observed excess cumulative allele numbers. The
empirical CIs for these cumulative allele frequencies
were estimated using 5000 bootstrap samples. The
bootstrap samples were created by sampling with replacement using subjects as the sampling unit. These
calculations were performed using in-house functions
in R. Significance was assessed using a false discovery rate <0.25.

RESULTS
Cardiomyopathy Subject Selection and
WGS
Subjects with nonischemic DCM (n=70) or HCM (n=56)
with familial disease were selected for WGS analysis
(Table 1). Detailed family history of cardiomyopathy
was available for all subjects. Subjects were retrospectively recruited from specialized clinics at the University
of Chicago, Stanford University, University of Michigan,
and Northwestern University. Genetic ancestry was
determined using PCA of ≈5 million biallelic markers,
and individuals were classified as African and non-
African based largely on principal component (PC) 1.
Genetic analysis revealed that one pair of individuals
was distantly related (half uncle relation), and subjects
were otherwise unrelated. At the outset, 35 individuals with MYH7 mutations were selected for the HCM
cohort. These MYH7-mutation carriers served as an
internal control when identifying genes/pathways enriched for genetic burden.
To focus on missense protein coding variation,
only nsSNVs were studied. After excluding insertion/
deletions, missense variants accounted for 96% of
total variants, and nonsense variants constituted the
remaining 4%. More than one platform was used
for WGS, and the number of single-nucleotide variants identified across platforms did not differ (t test;
P=0.32; R2=0.008). A cardiomyopathy gene list (102
genes) was generated from commercial testing panels, and only 89 of the 102 genes had variation in the
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Table 1. Demographic Characteristics of Cohort Subjects
Demographics

Dilated Cardiomyopathy

No.

Hypertrophic Cardiomyopathy

P Value

70

56

Male sex, n (%)

42 (60)

32 (57)

0.48

Age, mean±SD, y*

39±16

45±15

0.08†

Genetic race, n (%)
African ancestry

18 (25)‡

6 (11)

0.04

Non-African ancestry

53 (75)

50 (89)

0.04

0 (0)

35 (62)

<0.0001

Ascertained for MYH7‡

The χ2 test was performed, unless otherwise noted.
*Age at presentation.
†
Nonparametric unpaired Mann-Whitney test was performed. Individuals classified as Hispanic and other were reclassified as non-African ancestry on the
basis of genetically determined best-fit ancestry.
‡
Individuals selected on the basis of clinical genetic testing that returned a variant in MYH7.

sequenced cohort (Table S1). When evaluating these
102 genes, 10 357 nsSNVs were identified across the
126 genomes, and missense variation accounted for
97.4% of all variants. Table S2 provides the distribution
of nsSNVs per person in 102 cardiomyopathy genes
for DCM and HCM. Pathogenic, likely pathogenic,
and suspicious variants of uncertain significance were
identified in each subject and curated using evidence
from ClinVar and expert input (Table S3).

PCA of Echocardiographic Measures
Downloaded from http://ahajournals.org by on May 4, 2021

Echocardiographic LV measurements were used to
correlate genetic data with phenotype. Cardiac dimensions were normalized to BSA. LVEF, LVIDd, IVSd, and
LVPWd were significantly different between the DCM
and HCM cohorts, consistent with the primary diagnosis (Figure S1 and Table 2). PCA was performed on
measures of LVEF, LVIDd/BSA, IVSd/BSA, and LVPWd/
BSA. Figure S2A shows that the first PC of echocardiographic measures (PC1) accounted for 59% of the
variance, whereas PC2 accounted for 25%, PC3 accounted for 11%, and PC4 accounted for 5% (Table S4
and Figure S2A). Figure 1A illustrates that echocardiographic PC1 reliably separated cardiomyopathy subtypes, in addition to explaining most of the variance.

Component loadings of each phenotype demonstrated
the contribution of LV functional measures to the first
2 components (Figure S2B). Collectively, this suggests
that echocardiographic PC1 is a simple quantitative
variable for illustrating the echocardiographic differences between DCM and HCM.
To determine if the variability of echocardiographic
PC1 could be partially explained by cumulative
genetic factors, we queried the number of nsSNVs
per person in the 102 cardiomyopathy genes.
Regression of echocardiographic PC1 against the
number of nsSNVs per person in cardiomyopathy
genes was significant (n=126; P=0.0019), indicating
that the number of nsSNVs per person contributes
to the echocardiographic differences between
DCM and HCM (Figure 1B). This model using total
cardiomyopathy gene nsSNVs per person (n=10 357
total variants), as a linear predictor, accounted for
11.5% of the variance of echocardiographic PC1. To
determine the contribution of pathogenic variants/
likely pathogenic variants/suspicious variants of
uncertain significance, the analysis was performed
adjusting for pathogenic variants/likely pathogenic
variants/suspicious variants of uncertain significance
(Table S3; n=71), and this did not affect significance
or size of effect. In addition, a supporting subgroup

Table 2. LV Measurements Derived From Echocardiograms in Cardiomyopathy Cohort
Dilated
Cardiomyopathy

Measure
No.
Age at echocardiogram, mean±SD, y (N)
Ejection fraction, %, median (IQR) (N)
Left ventricle internal diameter, diastole/BSA, median (IQR), cm/m2 (N)
Interventricular septum, diastole/BSA, median (IQR), cm/m2 (N)
Left ventricle posterior wall thickness, diastole/BSA, median (IQR), cm/m2 (N)

Hypertrophic
Cardiomyopathy

P Value

70

56

41±16 (61)

47±14 (48)

0.06*

21 (15–35) (61)

65 (60–70) (48)

<0.0001

3.1 (2.9–3.7) (43)

2.3 (2.0–2.6) (45)

<0.0001

0.5 (0.47–0.60) (39)

0.85 (0.70–1.1) (46)

<0.0001

0.51 (0.44–0.59) (39)

0.61 (0.52–0.72) (45)

0.002

2

Measurements were normalized to BSA (m ), where indicated. The t test was performed, unless otherwise noted. BSA indicates body surface area; IQR,
interquartile range (first and third quartiles); and LV, left ventricular.
*Nonparametric unpaired Mann-Whitney test was performed.
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Figure 1. Principal component analysis (PCA) of echocardiographic data separates hypertrophic
cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) and is predicted by the number of
nonsynonymous single-nucleotide variants (nsSNVs) in cardiomyopathy genes.
A, PCA of echocardiography data shows that echocardiographic principal component 1 (Echo PC1)
summarizes the difference in echocardiography data between HCM (red) and DCM (black). B, Regression
of Echo PC1 against the number of cardiomyopathy gene nsSNVs/person was significant and effectively
separated HCM and DCM, as seen by the solid gray line (n=82). To account for genetic ancestry, linear
regression was repeated in the absence of African ancestry (n=70) subjects (dashed gray line) or Hispanic
ancestry (n=73) subjects (dot-dash gray line) or using only the European ancestry (dotted gray line; n=58)
subjects. *P=0.024, **P=0.005, ***P=0.002, †P=0.069.
Downloaded from http://ahajournals.org by on May 4, 2021

analysis was performed to determine if the trend
remained consistent within ethnically homogeneous
groups. When subjects with either Hispanic or African
ancestry were removed, the estimates remained
significant (P=0.005 and n=73 and P=0.024 and
n=70, respectively; Table S5). When the sample was
restricted to only European ancestry subjects, reducing
the number of subjects by a third, the general trend
remained unaffected, with a borderline significant P
value (P=0.069). Together, these data indicate that
the variance in echocardiographic PC1 is, in part,
explained by the number of cardiomyopathy gene
nsSNVs per person. As a control, we also considered
sequencing platform in addition to echocardiographic
PC1 and nsSNVs, and this resulted in no change
in the coefficient (0.039, for both models) slope or
significance (P=0.002) (Figure S3). Together, these
data indicate that greater protein coding variation
in cardiomyopathy genes accounts, in part, for the
differences in LV measures between DCM and HCM.

Probability of DCM Relative to
HCM Increases With the Number of
Cardiomyopathy Gene nsSNVs
To illustrate the association between these cardiomyopathy subtypes and the number of cardiomyopathy

gene nsSNVs per person, a simple generalized multivariate linear model was fitted using a standard
stepwise procedure based on analysis of deviance
and Akaike Information Criterion. Because DCM and
HCM genome sequencing was imbalanced across
sequencing platform, it was included as an adjustment to the model (Table S6). Adding the number
of cardiomyopathy gene nsSNVs per person to the
model significantly improved the fit and the ability to
predict DCM in this cohort (Table S6; P=0.021), and
this analysis demonstrates a cumulative genetic factor model where having more nsSNVs predisposes
to DCM (Figure 2). Adding genetic ancestry to this
model neither improved the fit nor negated the contribution of the number of nsSNVs, thus showing a
robust dependency between cardiomyopathy subtype and number of nsSNVs (Table S6).
We assessed the contribution of moderate population frequency nsSNVs, defined by gnomAD
exome global frequency (Figure 2, right panel). We
found that the per-person number of cardiomyopathy gene nsSNVs in the 25% to 50% population
frequency spectrum predicted DCM versus HCM
using a nested model with platform and number of
nsSNVs, similar to the above analysis (analysis of
deviance=0.023; Table S6). Although adding ancestry to the model improved fit, it did not change the
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Figure 2. Dilated cardiomyopathy (DCM) probability is increased with cardiomyopathy gene nonsynonymous single-
nucleotide variant (nsSNV) number compared with hypertrophic cardiomyopathy (HCM).
Multivariate generalized linear models demonstrate that the probability of DCM is increased with the total number of cardiomyopathy
gene nsSNVs per person in this cohort (left panel). The red and black dots represent individual participants and their number of
nsSNVs in cardiomyopathy genes. The analysis on the left considered all nsSNVs in cardiomyopathy genes, including rare and high-
frequency variants. The right-hand panel shows the same analysis when considering only high-frequency cardiomyopathy gene
nsSNVs, where the same trend was evident (allele frequency, 0.25–0.50 variants included). DCM is black, and HCM is red. P values
after adjustment for platform prevalence imbalance are shown (see Table S5). Number on x axis indicates the number of nsSNVs per
subject.
Downloaded from http://ahajournals.org by on May 4, 2021

coefficient (0.110 for number of nsSNVs). Using nsSNVs from genes with low expression in the heart
showed no ability to predict the probability of DCM
and HCM (Table S6). We also completed an analysis using additional frequency bins and found no
qualitative difference in the direction of the effect
(Table S7 and Figure S4). Although underpowered to
evaluate all frequency subsets, these data suggest
that the number of nsSNVs per person predicts DCM
compared with HCM across the frequency spectrum. Together, these data indicate that the number
of cardiomyopathy gene nsSNVs associates with the
DCM cardiomyopathy subtype.

Number of Cardiomyopathy Gene nsSNVs
Associates With Disease Severity in DCM
To interrogate the relationship between the number of
cardiomyopathy gene nsSNVs and disease severity,
we regressed individual LV measures against the number of nsSNVs per person in cardiomyopathy genes
(Figure 3A and 3B). Reduced LVEF and increased
LVIDd were each significantly dependent on the number of cardiomyopathy gene nsSNVs per subject with
DCM (Table S8). In subjects with HCM, the number
of cardiomyopathy gene nsSNVs was not significantly
associated with either LVEF or LVIDd (Table S8). IVSd

and LVPWd, both hallmarks of HCM, also showed no
association with cardiomyopathy gene nsSNV number
(Table S8).
To determine if these results were specific for
cardiomyopathy gene nsSNVs and not the result of
overall genomic burden, we separated all genes into
either high or low cardiac expression groups using
gene expression levels derived from genotype-tissue
expression (see Data S1 and Figure S5). We used
low expression heart genes to determine if the association between LV measures and cardiomyopathy
gene number nsSNV was specific, reasoning that
low expression heart genes should play a lesser role
in LV function. We considered variation per person in
89 randomly selected genes from the low-expression
heart genes to match the 89 cardiomyopathy genes
that carry variation in the HCM/DCM cohort, and repeated this process 1000 times. Using both total and
25% to 50% allele frequency, nsSNVs from these randomly selected low-expression heart genes revealed
minor qualitative trends; however, no statistical association between LVEF, LVIDd, IVSd, or LVPWd with
nsSNV count was observed (Figure 3C and 3D and
Table S9). We cannot exclude that a type II error is
not driving these results; however, total nsSNVs encompass cardiomyopathy nsSNVs and therefore will
provide a weaker, but nonzero, predictor.
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Figure 3. The number of cardiomyopathy gene nonsynonymous single-
nucleotide variants
(nsSNVs) per person associates with reduced cardiac function and increased left ventricular (LV)
diameter.
LV ejection fraction (LVEF) (A) and left ventricular internal diameter end diastole (LVIDd), normalized to
body surface area (BSA) (B), were regressed against the total number of cardiomyopathy gene nsSNVs per
person. Cardiomyopathy gene nsSNV number significantly correlated with reduced LVEF and increased
LVIDd in subjects with dilated cardiomyopathy (DCM), and this correlation was not seen for subjects with
hypertrophic cardiomyopathy (HCM) (*LVEF DCM P=0.01; HCM P=0.78; **LVIDd/BSA DCM P=0.02; HCM
P=0.34); gray shading represents 95% CIs (see Table S6 for values). A randomly selected group of genes
with comparable variant numbers was chosen from the low-expression heart genes and similarly tested.
This process was repeated 1000 times with different groups of genes. LVEF (C) and LVIDd/BSA (D) were
regressed against low-expression heart genes, and the regression lines did not reveal any significant
association with LV measures. Dashed lines represent 95% CIs (see Table S8 for values).

Together, these results indicate that the probability
and severity for each subject with DCM, relative to subjects with HCM, are associated with increasing nonsynonymous variant load in cardiomyopathy genes.

Genes With Deviant Cumulative Variant
Frequency in DCM and HCM
To identify candidate genes that contribute to the differences in variant load between DCM and HCM, we
investigated if any genes had aberrant cumulative
variant frequencies compared with gnomAD exome
frequency data. Ancestral allele frequencies were
compared with the allele frequencies in each bootstrap

sample, generating excess cumulative allele frequencies for each gene, and this process was repeated
5000 times. The resulting values for DCM and HCM
were subtracted from each other to produce Delta
(schematic shown in Figure S6).
Three cardiomyopathy genes had excess cumulative frequencies that were statistically significant at
false discovery rate <0.25 (Figure 4).19 We originally selected 35 of 56 subjects with HCM based on MYH7
variant carrier status, so, if reliable, the bootstrap
method should identify MYH7 variation as enriched
in the HCM cohort and serve as an internal control.
MYH7 was significantly enriched for variation in the
HCM cohort. LMNA was significantly enriched in DCM,
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Figure 4. Resampling identifies genes with deviant cumulative missense allele frequencies that
may modify dilated cardiomyopathy (DCM) or hypertrophic cardiomyopathy (HCM).
The bootstrap method (5000 resampling with replacement tests) was used to identify excess nonsynonymous
single-nucleotide variant burden in DCM compared with HCM (Delta) in either cardiomyopathy genes (A)
or high-expression heart genes (B). When conducting this analysis on cardiomyopathy genes, MYH7 and
BAG3 were identified as having increased cumulative variation in HCM. MYH7 was expected to appear
in this analysis because MYH7 mutations were enriched in the HCM cohort, and thus serve as an internal
control for this approach. From known cardiomyopathy genes, BAG3 was identified as being enriched in
HCM over DCM, and LMNA variation was enriched in DCM over HCM. This bootstrap method was applied
across all high expressed cardiac genes and identified potential novel modifiers of HCM and DCM.
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fitting well with LMNA’s known role in the pathogenesis
of DCM.20 Together, these data support this method
of calculating deviant allele frequencies while adjusting
for ancestry and sex.
We repeated the bootstrap analysis on genes with
high heart expression (as defined in Figure S5). In this
exploratory analysis of 7306 cardiac genes, 8 had
excess cumulative frequencies that differed between
HCM and DCM with a false discovery rate <0.25
(Figure 4B). Table S10 provides, in ranked order, the
genotype-tissue expression levels in heart for these
genes and any previous genome-
wide association
study from the genome-wide association study catalog (https://www.ebi.ac.uk/gwas). Two of these genes,
ANKRD9, encoding ankyrin repeat domain 9, and
CD36, encoding the thrombospondin receptor, have
previously been associated with cardiac phenotypes
of QT interval and LV mass, respectively.21,22

DISCUSSION
Cardiomyopathy Gene Variation Differs
Between DCM and HCM
Cascade family testing for primary gene mutations
highlights the range of clinical expression seen with
genetic variants.23 Environmental factors and other genetic variants contribute to this variable expressivity. In
this report, we identified that the number of nsSNVs
in cardiomyopathy genes correlated with DCM but

not HCM. Notably, we found the number of nonsynonymous variants in cardiomyopathy genes correlated
not only for DCM diagnosis compared with HCM, but
also for specific aspects of DCM, including reduced LV
function and increased LV size. These findings were
evident in cardiomyopathy genes and were not present
in low-expression heart genes.
Identifying common variation that contributes to
cardiomyopathy disease expression would aid in the
development of genomic risk scores for cardiomyopathy. A large-scale genome-wide association study and
multitrait analysis in HCM, DCM, and LV traits from UK
Biobank participants with healthy hearts revealed loci
associated with each cardiomyopathy subtype and with
LV measures.24 The study identified strong genetic correlations with the cardiomyopathies and LV traits. We
also identified correlations with cardiac dimensions and
cardiomyopathy subtype. The authors further generated polygenic risk scores and found that for subjects
with HCM carrying a rare, disease-
causing variant,
common variation accounted for phenotypic variability
in subjects with HCM. Our data are consistent with this
concept (namely, that common variation is contributing
to disease variability in the cardiomyopathies).

Oligogenic Inheritance in Cardiomyopathies
and Implications for Genetic Testing
In light of the reduced penetrance and expressivity of
familial cardiomyopathies, modifying factors of disease
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have been postulated.11 We now identified potential
modifiers of cardiomyopathy using a random resampling method. We identified expected genes, including
MYH7 in HCM and LMNA in DCM. The identification
of additional variants that may act in concert to cause
disease or affect severity suggests oligogenic inheritance. Functional experiments using CRISPR-
Cas9
now allow testing of multiple variants in concert. Recent
work by Gifford and colleagues identified a family with
asymptomatic parents and 3 children with early-onset
heart disease.25 Exome sequencing revealed a complex inheritance, with 3 variants likely contributing to
disease. In vivo gene editing techniques revealed that
variants in MKL2, MYH7, and NKX2-5 act together
to cause LV noncompaction. The 2 variants in MKL2
and MYH7 were paternally inherited and unique to the
family, whereas the maternal NKX2-5 allele was rare.
Experimental modeling confirmed the role of these
variants in disease and established NKX2-5 as a modifier of disease. These data support our hypothesis that
modifying variants may make a significant contribution
to disease phenotype.
Despite progress, likely pathogenic or pathogenic
variants are found in less than half of cases, depending on the type of cardiomyopathy.26 Recent work by
Haas et al used deep sequencing of 76 cardiomyopathy genes in a large cohort of 639 people with DCM
and found that >38% patients had compound or combined rare mutations, further supporting oligogenic
contribution.20 Cowan and colleagues reexamined
19 pedigrees with LMNA-associated cardiomyopathy
with cardiomyopathy-positive family members who did
not have the “causal” LMNA gene variant, suggesting additional genetic causes of disease.27 In a large
DCM cohort with 1040 subjects, Mazzarotto et al sequenced 56 cardiomyopathy genes and found robust
disease association with 12 of those genes, explaining
17% of cases and 26% of cases in a validation cohort
with 1498 subjects.28 Our data indicate that variant
load plays an important role in both the manifestation
and severity of DCM. The clinical utility of knowing variant load and how this relates to an individual’s disease
progression is not established and requires additional
study. However, the concept of oligogenic inheritance
in DCM provides one path to better understanding
variable expressivity. Highly penetrant, rare variants
provide risk knowledge, and additional variants may
ultimately help refine that risk.
In this study, we examined the genetic landscape that
differentiates DCM and HCM using a cohort in which
individual-
level data, both clinical and genetic, were
available. To define genetic drivers of cardiomyopathy,
a large well-phenotyped and genotyped control data
set is required. Current data sets, such as gnomAD
and others, provide a rich source of population-level
allele frequency information. However, these data sets,
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by design, cannot be used to parse the contributions of
allele combinations on disease state because they provide aggregate data. Moving the forefront of precision
medicine requires deep sequencing and phenotype information while protecting subjects’ privacy.
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Data S1.
EXPANDED MATERIALS & METHODS
Study subjects. Non-ischemic dilated or hypertrophic cardiomyopathy subjects with familial
disease were selected for whole genome sequencing (WGS). Detailed family history of
cardiomyopathy was available for all subjects. Subjects were retrospectively recruited from
specialized clinics at the University of Chicago, Stanford University, University of Michigan and
Northwestern University. Subjects were selected based on a diagnosis of familial non-ischemic
dilated cardiomyopathy or familial hypertrophic cardiomyopathy. Preference was given to
subjects who had previous genetic testing and for whom a primary mutation was not identified,
except in the case of selected MYH7 variants and for whom echocardiographic data was
available. Echocardiographic measurements were excluded if age at test was ≤ 17 years old or
if the subject had a myectomy.
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Generation of whole genome sequence data. Genomic DNA was extracted from peripheral
blood. Sequencing was performed using the Illumina HiSeq2000, 2500 or XTen to greater than
30X coverage. Paired-end reads were mapped to NCBI reference genome hg19. Reads were
aligned and variants were called using MegaSeq, a supercomputing pipeline using the open
source Burrows Wheeler Aligner (BWA) and Genome Analysis Tool Kit (GATK).18 Variant
effects were predicted using snpEff.19 Variant frequencies were annotated using frequencies
from the gnomAD database (http://gnomad.broadinstitute.org/) accessed in March 2018. Allele
frequencies are reported as global, EA (non-Finnish European ancestry) or AA (African
ancestry) for each variant. When population allele frequency was used, only dataset variants
with gnomAD exome coverage ≥ 8X were included in the analysis. Indels and multi-allelic
variants were removed from the working dataset. Relatedness was accounted for using PLINK.
Ancestry principal component analysis (PCA). PCA was used to estimate global ancestry
through dimensional reduction. The 1st and 3rd component illustrated ancestry. PCAs were
conducted using singular-value decomposition of shared variants using ~5 million biallelic
variants selected from across the genome using PLINK v1.9 and R 3.2.3.
Cardiomyopathy gene selection. Cardiomyopathy genes were identified based on their
inclusion in one or more Cardiomyopathy gene testing panels of Partners Healthcare Laboratory
for Molecular Medicine, GeneDx, and Invitae.
Dichotomizing heart genes into high and low expression. The Genotype-Tissue Expression
(GTEx) database version 6p was downloaded Dec 2016 (https://www.gtexportal.org). The
GTEx dataset includes RNA sequence analysis of human left atrial appendage (referred to as
AA in GTEX, n=264 samples, and referred to as LA in this report) and left ventricle (LV, n=272).
Expression values in RPKM (Reads Per Kilobase Million) for left ventricle (LV) and atrial
appendage (AA) were used for genes identified as having variation in the DCM and HCM WGS
dataset (17,058 genes with a total of 1,744,423 variants). Chromosome Y was removed that
included 13 genes with 105 variants leaving 17,045 genes and 1,744,318 variants. Genes
without cardiac GTEx values were removed leaving 16,825 genes and 1,729,723 variants.
Variants with gnomAD exome coverage less than 8X were excluded leaving 16,353 genes and
1,635,325 variants. Genes with known segmental duplications were also removed
(genome.ucsc.edu; GenomicSuperDups Table, assessed March 2018), leaving 14,915 genes
and 1,252,213 variants. For these genes, RPKM values for LV were plotted against RPKM

values for AA as logarithms. We overlaid the cardiomyopathy genes on this plot to create an
expression space that encompasses genes expressed in the heart.
Echocardiographic Data. 2-D echocardiographic measures were collated retrospectively from
health records. Left ventricular ejection fraction (EF), left ventricular internal diameter end
diastole (LVIDd), interventricular septal end diastole (IVSd), and left ventricular posterior wall
end diastole (LVPWd) and body surface area were collected when available. If multiple
echocardiograms were available, the study with the most abnormal measures was used. For
DCM subjects, lowest EF was selected while for HCM subjects thickest IVSd was selected. All
measures were taken from only one study date.
Echocardiography PCA. Principal component analysis (PCA) was performed using the R
function prcomp (R statistical software version 3.4.1) on scaled and centered left ventricular
ejection fraction, left ventricular internal diameter end diastole (LVIDd), interventricular septal
end diastole (IVSd), and left ventricular posterior wall end diastole (LVPWd). All dimensions
were adjusted to body surface area (BSA). Variables were centered by subtracting the mean
and scaled by dividing by the standard deviation to prevent measurement units from
determining their importance.
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Linear models. Multivariate and univariate linear models were fit using the lm function of R (R
statistical software version 3.4.1). Models were ranked in order of complexity (from one to four
explanatory variables). Models of the same complexity were compared using t-tests provided
by R and estimated r-squared values, while nested models were compared using the R anova
function to estimate whether additional variables improved the fit significantly. Model
significance was assessed using a chi-squared test on reduction in the residual sum of squares.
Regression against random samples of genes were performed by randomly selecting 89 genes
from the noncardiac gene list. 89 genes were selected to match the number of genes in the
cardiomyopathy genes with nsSNVs. The sample was checked to ensure that the minimum and
maximum number of variants in the randomly selected set were within 1 standard deviation from
the minimum and the maximum number of variants of the 89 cardiomyopathy genes. This was
repeated until 1000 sets met criteria. Linear regression of phenotype against these gene sets
was performed as above. Confidence intervals were estimated directly from the sample.
Generalized linear model (GLM). Multivariate and univariate generalized linear models (GLM)
were fit using the R function, glm, with binomial link function, fit to a logistic model. Models were
generated using all nonsynonymous single nucleotide variants (nsSNVs) as primary analysis as
well as variant frequency subsets defined by gnomAD exome allele frequency in both the
cardiomyopathy genes and across all low-expression heart genes. To control for the potentially
confounding effects of sequencing platform and genetic ancestry, a standard step-wise
approach was used selecting the best-fit model and adding additional variables (sequencing
platform, race and number of nsSNVs) until either the Akaike information criterion (AIC)
increased or Analysis of Deviance (R function anova) showed non-significant improvements.
Additional variables were excluded if they did not qualitatively change the contribution of
variants to the fit by comparing the estimated coefficient values. P values correspond to the R
anova (Analysis of Deviance test) function and therefore refer to the overall model.
Resampling based estimation of excess nonsynonymous variation. See Figure S5 for
schematic. Allele counts were aggregated by variant, sex, race, and cardiomyopathy type to
create relatively homogeneous subsets. Differences in variant frequencies due to race were
compensated for using gnomAD exome allele frequencies for African (AFR) or European
ancestry (NFE). Sex was corrected for by only counting one allele and one chromosome per

male for chromosome X variants. Based on the number of chromosomes in the race and
cardiomyopathy subset of the cohort, the expected allele numbers using ancestral gnomAD
frequencies were calculated and subtracted from the observed alleles in the subset to re-center
allele number around the expected value. These re-centered allele numbers were summed
over each of the cardiomyopathy genes, then in high-expression heart genes set (as defined in
Figure S5) creating observed excess cumulative allele numbers. Allele numbers were divided
by the total number of chromosomes in each bootstrap. The empirical confidence intervals for
these cumulative allele frequencies was estimated using 5,000 bootstrap samples.30 As proof of
principle, we analyzed cardiomyopathy genes and identified genes with significant differences
between the subtypes. The bootstrap samples were created by sampling with replacement
using subjects as the sampling unit. These calculations were performed using in-house
functions in R. Significance for the difference between the cardiomyopathy types was estimated
using the empirical quantiles of the distribution of the bootstrap sample differences,
corresponding to a false discovery rate of 0.25, following the Benjamini-Hochberg method.20
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Table S1. Cardiomyopathy Genes.
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A2ML1

DOLK

JUP

NEXN

SLC22A5

ABCC9

DSC2

KRAS

NF1

SOS1

ACTC1

DSG2

LAMA4

NKX2-5

SOS2

ACTN2

DSP

LAMP2

NPPA

SPRED1

AGL

DTNA

LDB3

NRAS

TAZ

ALPK3

EMD

LMNA

PDLIM3

TCAP

ANKRD1

EYA4

LRRC10

PKP2

TGFB3

BAG3

FHL1

MAP2K1

PLEKHM2

TMEM43

BRAF

FHL2

MAP2K2

PLN

TMPO

CACNA1C

FKRP

MIB1

PRDM16

TNNC1

CALR3

FKTN

MURC

PRKAG2

TNNI3

CASQ2

FLNC

MYBPC3

PTPN11

TNNT2

CAV3

GAA

MYH6

RAF1

TPM1

CBL

GATA4

MYH7

RASA1

TRDN

CHRM2

GATA6

MYL2

RBM20

TTN

CRYAB

GATAD1

MYL3

RIT1

TTR

CSRP3

GLA

MYLK2

RRAS

TXNRD2

CTF1

HCN4

MYOM1

RYR2

VCL

CTNNA3

HRAS

MYOZ2

SCN5A

DES

ILK

MYPN

SGCD

DMD

JPH2

NEBL

SHOC2

HUGO Gene names.

Table S2. Distribution of cardiomyopathy nsSNVs.

Phenotype
DCM
HCM

1st quartile
71
68

Median
85
78

3rd quartile
95.8
91
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Table S3. Pathogenic/Likely Pathogenic/Suspicious VUS in HCM and DCM subjects.
Gene

Variant

Variant Designation

Segregation

ACTA1
BAG3
DES
DMD
DSP

p.W358S
p.Q244*
c.735+3A>G
dup exons 3-9
p.E1245_N1246fs
p.Y1065*
c.3791G>C
p.C1013*

sVUS
LP
P
P
LP
P
sVUS
P

N/A
Yes
Yes
Yes
Yes
Yes
N/A
N/A

p.T291_V292fs
p.S2457fs
p.R118C
p.R433H
p.D1063_K1064fs
c.1224T>G
p.W1097*
p.L156P
p.P16S
p.E541Q
p.R495Q
R255*
p.A1004S
p.R1250W
p.M982T
p.L908V
p.A355T
p.H576R
p.G1057S
p.R663H
p.E1468K
p.G716R

P/LP
P
sVUS
LP
LP
P
P
sVUS
LP
P
P/LP
LP
P
LP
sVUS
P
P
LP
sVUS
P
sVUS
P

N/A
N/A
Yes
N/A
Yes
N/A
N/A
N/A
N/A
Yes
Yes
Yes
N/A
Yes
Yes
Yes
N/A
N/A
N/A
N/A
N/A
N/A

p.K847E
p.A797T

LP
P

N/A
N/A

p.G1057D
p.R1606C

sVUS
sVUS

N/A
N/A

p.R719W
p.R869H

P
sVUS

N/A
N/A

FLNC

GLA
LMNA
MYBPC3
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MYBPHL
MYH6
MYH7

MYH7

RBM20
SCN5A
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TNNT2

p.P731A

sVUS

N/A

p.N1327K
p.I736T
p.V320M
p.E497D
p.D906G
p.D469N
p.R204H
p.T1377M
p.G741W
p.R1712Q

sVUS
P
LP
P
P
sVUS
LP
LP
P
LP

N/A
N/A
N/A
N/A
N/A
N/A
Yes
N/A
N/A
N/A

p.E1455K
p.R652G
p.R403Q
p.R783H
p.R634Q
p.R636H
p.R814W
p.G1318V
p.Arg1316*
K210del

sVUS
LP
P
LP
P
P
LP
P/LP
LP
sVUS

N/A
Yes
N/A
N/A
Yes
Yes
Yes
Yes
Yes
Yes

p.N274D
sVUS
N/A
TPM1
p.D230N
P
Yes
p.E54K
P/LP
N/A
p.Leu254fs
sVUS
N/A
TTN
p.E3707*
LP
Yes
p.Phe20604_Leu20605fs
P
Yes
c.42521–5 C>G
sVUS
Yes
p.Tyr15330*
sVUS
N/A
p.R4386*
sVUS
N/A
c.17087G>A
sVUS
Yes
p.Val14761fs
sVUS
N/A
p.Leu18170fs
sVUS
N/A
p.Gly14825*
sVUS
N/A
p.R12136*
LP
N/A
*P=pathogenic, LP=likely pathogenic, sVUS= suspicious variant of uncertain significance; as
adjudicated using ClinVar, frequency data, subject phenotype and expert opinion. Proband
and at least one other affected relative carry the variant. N/A= not available

Table S4. PCA Weights for Left Ventricular Measures.

IVSd_BSA
LVPWd_BSA
LVIDd_BSA
EF (%)
Proportion of
Variance
Cumulative
Proportion

PC1
0.52
0.29
-.056
0.57

PC2
-0.25
-0.84
-0.39
0.28

PC3
-0.81
0.44
-0.17
0.36

PC4
-0.08
0.13
-0.71
-0.68

0.59

0.25

0.11

0.05

0.59

0.84

0.95

1.00

PCA weights obtained by applying the R function prcomp to echocardiographic measures.
PCA= principal component analysis
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Table S5. Linear regression of PC1 against ancestry subsets.

Model
V(all)*
No HA
No AA
Only EA

Number of
subjects
82
73
70
58

Coefficient
0.0391
0.0372
0.0314
0.0272

p value
0.0019
0.0055
0.0243
0.0691

*V(all) = total cardiomyopathy gene nsSNVs; Genetic ancestry
abbreviations: HA = Hispanic ancestry; AA = African ancestry; EA =
European ancestry.
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Table S6. Nested Generalized Linear Model Fits Adjusting for Ancestry and Sequencing
Platform.
Model
Variables
Platform
nsSNVs
Ancestry
Platform &
nsSNVs
Platform &
Ancestry
Platform &
nsSNVs &
Ancestry

Degree of
Model
1
1
1
2
2

Coefficient
Coefficient
Ancestry
nsSNV
p value*
Total nsSNVs in cardiomyopathy genes
4.15 x 10-5
0.026
0.053
1.040
0.042
0.025
0.034
(nsSNVs)
0.043
1.11
(Ancestry)

Analysis of
Deviance

AIC
160.2
174.41
173.69

0.021

156.85

0.034

157.71
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3
0.719
0.025
0.224
nsSNVs in cardiomyopathy genes with gnomAD Frequency 0.25-0.50
Platform
1
4.15 x 10-5
nsSNVs
1
0.095
0.037
Ancestry
1
1.040
0.042
Platform &
0.027
nsSNVs
2
0.110
(nsSNVs)
0.023
Platform &
0.043
Ancestry
2
1.11
(Ancestry)
0.034
Platform &
nsSNVs &
Ancestry
3
1.11
0.110
0.037
Total nsSNVs in low expression heart genes
Platform
1
-1.59
4.15 x 10-5
nsSNVs
1
0.0008
0.027
Ancestry
1
1.04
0.042
Platform &
0.055
nsSNVs
2
0.0007
(nsSNVs)
0.045
Platform &
0.043
Ancestry
2
1.11
(Ancestry)
0.034
Platform &
nsSNVs &
Ancestry
3
1.02
6.11 x 10-5
0.494
nsSNVs in low expression heart genes with gnomAD Frequency 0.25-0.50
Platform
1
-1.59
4.15 x 10-5
nsSNVs
1
-0.002
0.28
Ancestry
1
1.04
0.042
Platform &
0.205
nsSNVs
2
-0.003
(nsSNVs)
0.045
Platform &
0.043
Ancestry
2
1.11
(Ancestry)
0.034
Platform &
nsSNVs &
Ancestry
3
1.68
0.003
0.064

157.37
160.2
173.76
173.69
157.03
157.71

154.67
160.2
172.83
173.69
158.17
157.71

159.17
160.2
177.09
173.69
160.55
157.71

159.12

*p value cutoff of 0.1 used to determine variables for nested models. Model with best fit is shaded
gray for each variable grouping. AIC=Akaike Information Criterion.
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Table S7. Number of nsSNVs in Each Frequency Bin.

nsSNV Frequency Bin
Total
0.25-0.50
0.1-0.25
<0.1
<0.01
<0.0025

Number of nsSNVs
10357
1788
1795
2472
1075
626
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Table S8. Linear regression of phenotype against V(all)*

Phenotype
LVEF
DCM
HCM
LVIDd/BSA
DCM
HCM
IVSd/BSA
DCM
HCM
LVPWd/BSA
DCM
HCM

Coefficient

P value

95% CI

-0.338
-0.032

0.012
0.779

-0.593 - -0.082
-0.258 – 0.193

0.017
0.005

0.024
0.344

0.003 – 0.031
-0.005 – 0.016

0.0001
-0.0008

0.934
0.830

-0.003 – 0.003
0.008 – 0.007

0.002
0.001

0.174
0.473

-0.235 – 0.239
-0.002 – 0.004

* V(all) = total nsSNVs in cardiomyopathy genes. LVEF, Left ventricular ejection
fraction; LVIDd/BSA, Left ventricular internal diameter at end diastole normalized
to body surface area; IVSd/BSA, Interventricular septal end diastole normalized
to BSA; LVPWd/BSA, Left ventricular posterior wall thickness at end diastole
normalized to BSA. 95% CI = 95% confidence intervals
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Table S9. Confidence Intervals for Simulated Linear Regression.

Phenotype
LVEF
DCM
HCM
LVIDd/BSA
DCM
HCM
IVSd/BSA
DCM
HCM
LVPWd/BSA
DCM
HCM

95% CI
-0.52 - 0.13
-0.33 - 0.32
-0.01 - 0.03
-0.01 - 0.02
-0.003 - 0.003
-0.01 - 0.01
-0.002 - 0.004
-0.004 - 0.005

LVEF, Left ventricular ejection fraction; LVIDd/BSA, Left
ventricular internal diameter at end diastole normalized to
body surface area; IVSd/BSA, Interventricular septal end
diastole normalized to BSA; LVPWd/BSA, Left ventricular
posterior wall thickness at end diastole normalized to BSA.
95% CI = 95% confidence intervals
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Table S10. Cardiac expression levels and GWAS Associations of Cardiac Genes.

GENE
NAME
MYH7
ANKRD9

GENE
Myosin heavy
chain 7
Ankyrin repeat
domain 9

Atria
GTEx
TPM
Rank*

Ventricle
GTEx
TPM
Rank*

563.7

3

4552

1

42.15

4

47.05

3
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CD36

thrombospondin
receptor

85.38

6

147.5

4

SOBP

Sine oculis
binding protein
homolog

9.15

32

7.23

38

AK2

Adenylate
kinase 2

23.88

40

18.05

43

GSPT1

G1 to S phase
transition

21.56

39

17.16

44

3.53

46

2.21

51

29.73

43

20.89

52

10.55

48

7.19

52

PC
MLLT6
RHBDD3

Pyruvate
carboxylase
PHD finger
containing
Rhomboid
domain
containing 3

GWAS Reported Trait
Resting Heart Rate
QT Interval; Blood
Protein Levels
LV mass; RBC width;
Mean corpuscular
volume; RBC count;
Platelet count; Mean
platelet volume; HDL;
Response to
fenofibrate
Airway
Responsiveness in
COPD; Myopia;
Alzheimer Age of
Onset
Gut microbiota;
Cerebral amyloid
deposition in APOEe4
non-carriers
Menopause (age of
onset); Testicular Germ
Cell Tumor
HIV-1 susceptibility

Breast Cancer;
Pancreatic Cancer

*Rank relative expression in relation to 53 tissues included in GTEx dataset
GWAS traits from the GWAS catalog (https://www.ebi.ac.uk/gwas). TPM= Transcripts Per
Million GTEx database (https://www.gtexportal.org, assessed June 2018)

Figure S1. Left ventricle measurements of DCM and HCM subjects determined by
echocardiography.

Downloaded from http://ahajournals.org by on May 4, 2021

(A) Left ventricular ejection fraction (LVEF), (B) Left ventricular internal diameter at end diastole
normalized to body surface area (LVIDd/BSA), (C) Interventricular septal end diastole
normalized to BSA (IVSd/BSA), and (D) Left ventricular posterior wall thickness at end diastole
normalized to BSA (LVPWd/BSA) are shown for subjects with DCM (black) and HCM (red),
(*p<0.05, t-test). DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy. DCM
participants had lower LVEF and larger LVIDd measurements, while HCM subjects had
increased IVS and LVPW compared to DCM, consistent with the primary diagnosis.

Figure S2. PCA metrics of cardiac phenotype.

PCA on echocardiographic measurements for the cardiomyopathy cohorts. A) Scree plot
showing the variance associated with each component. B) Component loadings of each
phenotype measurement on the principal components.
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Figure S3. Platform does not change the dependency between Echo PC1 and nsSNVs.
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PCA of echocardiography data revealed that PC1 summarizes the difference between HCM and
DCM. Regression of Echo PC1 against the number of cardiomyopathy gene nsSNVs per
person demonstrates SNV number distinguishes cardiomyopathy subtype. Platform was tested
to determine if the either of the two platforms used in this study were responsible for the
dependence of Echo PC1 on nsSNV number. These data indicate that platform does not cause
the dependency. Squares represent subjects. DCM, dilated cardiomyopathy (black); HCM,
hypertrophic cardiomyopathy (red). Solid gray line, Xten platform; dashed gray line, 2000/2500
platform.

Figure S4. The number of cardiomyopathy gene nsSNVs per person qualitatively predicts
DCM across frequency bins.
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Multivariate generalized linear models suggest that the probability of DCM increases with the
number of nsSNVs per person across frequency bins in this cohort. The red and black dots
represent individual participants and their number of nsSNVs in cardiomyopathy genes. (A) 0.10.25; (B) <0.1 (C) <0.01 and (D) <0.0025. DCM (black), HCM (red). Number on X axis indicates
the number of nsSNVs per subject.

Figure S5. Dichotomizing heart genes into high expression and low expression.
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The expression of all genes (light blue circles) and genes linked to cardiomyopathies (dark blue
triangles) was assessed in the Genotype-Tissue Expression (GTEx) database. Genes linked to
cardiomyopathy were those found in commercial and academic gene testing panels (n=102
genes). The logs of RPKM (Reads Per Kilobase Million) for the left atrium (left atrial
appendage, n=264 samples) and left ventricle (n=272 samples) were plotted against each other
for all genes with at least one variant in the HCM/DCM cohort (n=14915 genes in total). Ninetyeight genes of the 102 cardiomyopathy genes were contained in a well-defined subset of the
expression space bounded from below by the expression values for FKTN (GTEx LA = 2.00)
and CBL (GTEx LV = 1.49); denoted by the black dotted lines. All genes with GTEx values
below these cutoffs were considered low-expression heart genes (7,609 genes). All genes with
values equal to or greater than both of the above cutoffs constitute high-expression heart genes
(7,306) genes. Expression heat maps at each axis show increasing expression from red to
green. RPKM, reads per kilobase million.

Figure S6. Workflow to correct allele frequencies.
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Schematic illustrating ancestral allele frequency correction performed on each nsSNV. nsSNV
count was determined in cardiomyopathy and ancestry subgroups, and adjusted by gnomAD
ancestral allele frequency. Corrected allele frequencies were summed across each gene by
cardiomyopathy subgroup and ancestry. Delta is the difference in corrected allele frequency per
gene between DCM and HCM. snSNV=nonsynonymous sinlge

